Why the study?
Does losartan improve hemodynamic parameters in patients with symptomatic heart failure and ejection fraction < 40%?
Population
154 patients with symptomatic heart failure and impaired left ventricular function, of which 134 met the…
Comparison
Losartan 2.5, 10, 25, or 50 mg oral once daily… vs Placebo.
Design
RCT, double-blind
Follow-up
12 weeks
Authors
Discussion
Loading...
Member takes
Implication
Losartan improves hemodynamics in symptomatic HFrEF; extends ARB evidence to invasive parameters and supports outcome trials.
Structured PICO
Does losartan improve hemodynamic parameters in patients with symptomatic heart failure and ejection fraction < 40%?
P
Population
154 patients with symptomatic heart failure and impaired left ventricular function (ejection fraction < 40%), of which 134 met the protocol criterion of baseline pulmonary capillary wedge pressure >= 13 mm Hg.
I
Intervention
Losartan 2.5, 10, 25, or 50 mg oral once daily for 12 weeks.
C
Comparator
Placebo.
O
Outcome
Invasive 24-hour hemodynamic assessment (including systemic vascular resistance, blood pressure, pulmonary capillary wedge pressure, cardiac index, and heart rate) after the first dose and after 12 weeks of treatment.surrogate
Losartan at 25 mg and 50 mg once daily produces significant short- and long-term hemodynamic improvements in patients with symptomatic heart failure.
Cite This Study
Crozier et al. (1995) studied this question.